Big expectations, exits, and a rushed union are still testing the $14 billion Teladoc-Livongo merger one year in

Advertisement
Big expectations, exits, and a rushed union are still testing the $14 billion Teladoc-Livongo merger one year in
Livongo's IPO in July 2019. Livongo

Hello,

Advertisement

Welcome to Insider Healthcare. I'm healthcare editor Leah Rosenbaum, and today in healthcare news:

If you're new to this newsletter, sign up here. Comments, tips? Email me at lrosenbaum@insider.com or tweet @leah_rosenbaum. Let's get to it...


Teladoc acquired Livongo to recreate healthcare. A rushed union, a wave of senior exits, and sky-high expectations are testing the $14 billion bet.

Read the Insider investigation>>


Big expectations, exits, and a rushed union are still testing the $14 billion Teladoc-Livongo merger one year in
Registered nurse Alix Zacharski, left, receives a Pfizer COVID-19 booster shot from Douglas Houghton, right, at Jackson Memorial Hospital Tuesday, Oct. 5, 2021, in Miami. AP Photo/Lynne Sladky
An immunocompromised man had 4 shots of COVID-19 vaccine but still appears to have poor immunity

Dive in>>

Advertisement


The US had a Lyme disease vaccine decades ago - but the CDC, lawsuits, and conspiracy theories derailed it

Read more>>


More stories we're reading:


-Leah

{{}}